Miura et al. found that in HFD-induced hypercholesterolemia and steatohepatitis-related hepatocellular carcinoma (HCC) models, ezetimibe protects mice from HCC by reducing serum and liver cholesterol levels and inhibiting angiogenesis that were induced by CD31 and VEGF (vascular endothelial growth factor) (Miura et al., 2019). The gene discussed is VEGFA; the disease is familial hypercholesterolemia.